Tempus AI enters July with one of the more contradictory setups in the healthcare AI space: short interest has jumped nearly 20% in a single week, yet the stock itself rallied 19% over the same period and borrowing costs have fallen sharply.
Short interest is the most striking feature of the current positioning. At 21.4% of free float — up 39% over the past month — TEM carries one of the heavier short burdens in the life sciences sector. The week saw roughly 6 million additional shares added to the short book, pushing the count to around 37 million. That is a large absolute move. Yet the borrow market is telling a different story: cost to borrow has dropped 34% on the week to just 0.68%, a level more consistent with a routine growth-stock short than a high-conviction squeeze trade. Availability has also loosened relative to the tightest readings of mid-June, when it fell as low as 12% on June 15. It now sits at 41%, meaning roughly one share is still available for every 2.4 already lent out — tighter than normal but well off the near-fully-used conditions seen two weeks ago. The combination of rising short interest and falling borrow costs suggests new shorts are entering at a price they consider comfortable, not scrambling to press a position in a constrained lending pool.
Options traders shifted notably more cautious on the final day of June. The put/call ratio moved to 0.47 — more than two standard deviations above its 20-day average of 0.41 and the highest single-day reading in nearly a month. The jump is notable because the prior three weeks had seen the PCR hugging its lowest levels of the year, near 0.37. One day of elevated put buying does not define a trend, but it does mark a change in tone on the same day the stock gave back 0.65% after a strong run.
The Street sits in a cautious hold consensus, though the underlying analyst mix is more divided than that label implies. Bulls at Needham and BTIG maintain Buy ratings with targets of $75 and $80 respectively, both well above the current price of $57.93. TD Cowen raised its target to $68 after the last earnings print. On the other side, Jefferies initiated with an Underperform and a $35 target in April, and Freedom Capital Markets initiated at Hold with a $59 target just this week — roughly in line with where the stock is trading. The mean target of $66 implies about 14% upside from current levels, but the spread of views is wide. The bull case rests on platform defensibility and a path to positive free cash flow by year-end 2026. Bears point to negative earnings per share, an EV/EBITDA multiple near 100x, a price-to-book above 21, and dependence on VA ordering patterns and ASP expansion to make the numbers work. EPS estimates are being revised down even as revenue growth accelerates — the 30-day EPS momentum factor ranks in the bottom 5th percentile of the universe.
Insider activity adds a layer of caution. The 90-day net figure looks positive at face value — net 408,000 shares — but the recent trade log shows consistent selling. Founder and CEO Eric Lefkofsky sold over $7.7 million worth of stock on May 27 across multiple transactions. CFO Jim Rogers sold $634,000 on June 25 at $55. An independent director also sold on the same day. These are not distress signals, but a CEO reducing exposure into a 19% weekly rally is worth noting. Lefkofsky still holds over 41 million shares, so the sales represent a small fraction of his position — yet the pattern of selling into strength has been consistent through May and June.
The next earnings print is scheduled for August 4. The prior quarter produced a 2.9% one-day gain followed by a 9.5% five-day decline. The quarter before that reversed: a modest day-one gain became an 11.8% five-day rally. The ORTEX short score of 74.7 has been largely stable over the past two weeks, suggesting the current bearish positioning is already well-reflected rather than building toward a step-change. What the August report will test is whether revenue momentum is enough to start closing the gap between topline growth and earnings-per-share revisions — that is the tension the market is clearly pricing but not yet resolving.
See the live data behind this article on ORTEX.
Open TEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
